Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients
ECHO
1 other identifier
observational
2,467
1 country
32
Brief Summary
The aim of the present study is to estimate the national annual prevalence and incidence of current hepatitis C virus (HCV) infections among opioid dependent individuals in opioid substitution treatment (OST) based on a representative sample of approximately 2,500 outpatients in 100 substitution facilities across Germany. Furthermore, the study aims to describe factors influencing HCV therapy initiation and seroconversion during OST.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2014
Typical duration for all trials
32 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2014
CompletedFirst Submitted
Initial submission to the registry
March 16, 2015
CompletedFirst Posted
Study publicly available on registry
March 23, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2017
CompletedMay 31, 2017
May 1, 2017
2.7 years
March 16, 2015
May 29, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
National annual prevalence and incidence of current HCV infections among opioid dependent individuals in substitution treatment
12 months
Secondary Outcomes (2)
Patient questionnaire: Patient Reported Outcomes
1 month
Clinician questionnaire: Clinician Reported Outcomes and Data from Routine Patient Care
1 month
Study Arms (1)
HCV negative or in HCV treatment at T1
This group will be followed up at T2
Eligibility Criteria
Opioid dependent outpatients in opioid substitution treatment regardless of treatment setting
You may qualify if:
- minimum age 18
- diagnosed opioid dependence according to the ICD-10
- currently in opioid substitution treatment
You may not qualify if:
- severe mental impairment
- insufficient German reading and writing skills
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Prof. Dr. med. Jens Reimerlead
- Janssen-Cilag G.m.b.Hcollaborator
Study Sites (32)
Dr. Rudolf Dinkelacker
Crailsheim, Baden-Wurttemberg, 74564, Germany
Dr. Manfred Hartmann
Herrenberg, Baden-Württenberg, 71083, Germany
Dr. Reinhold Burr
Hirrlingen, Baden-Württenberg, 72145, Germany
Dr. Christoph von Ascheraden
Saint Blasien, Baden-Württenberg, 79837, Germany
Dr. Barbara Haider
Aichach, Bavaria, 86551, Germany
Dr. Eugen Fürmann
Augsburg, Bavaria, 86150, Germany
Dr. Astrid Beck
Fürstenfeldbruck, Bavaria, 82256, Germany
Dr. Winfred Dresel
Warngau, Bavaria, 83627, Germany
Dr. Monika Peter-Giglio
Bad Nauheim, Hesse, 61231, Germany
Dr. Andreas Weselek
Ehringshausen, Hesse, 35630, Germany
Dr. Georg Wetzig
Frankfurt am Main, Hesse, 60316, Germany
Dr. Christine Rose
Goslar, Lower Saxony, 38640, Germany
Dr. Uta Menschikowski
Parchim, Mecklenburg-Vorpommern, 19370, Germany
Dr. Georg Kramann
Achim, Niedersachen, 28832, Germany
Dr. Detmar Jobst
Bonn, North Rhine-Westphalia, 53229, Germany
Dr. Michel Voss
Cologne, North Rhine-Westphalia, 51065, Germany
Dr. Helmut Walter
Hamm, North Rhine-Westphalia, 59065, Germany
Dr. Manfred Plum
Herne, North Rhine-Westphalia, 44652, Germany
Dr. Martin Burger und Dr. Wolfgang Lüttecken
Münster, North Rhine-Westphalia, 48153, Germany
Dr. Astrid Weber
Koblenz, Rhineland-Palatinate, 56070, Germany
Dr. Liane Arimond
Trier, Rhineland-Palatinate, 54293, Germany
Dr. Maria Viehweger
Chemnitz, Saxony, 09130, Germany
Dr. Ernst Soldan
Norderstedt, Schleswig-Holstein, 22846, Germany
Dr. Alexander Cegla
Wenningstedt, Schleswig-Holstein, 25980, Germany
Dr. Gerd Klausen
Berlin, 10115, Germany
Dr. Clemens Micus
Berlin, 12043, Germany
Dr. Lutz Weinrich
Berlin, 12555, Germany
Dr. Wieland Tietje
Bremen, 28719, Germany
Dr. Nico le Claire
Hamburg, 20095, Germany
Dr. Felix Maas
Hamburg, 20357, Germany
Dr. Wirkner Thiel
Hamburg, 22043, Germany
Dr. Eckhard Zeigert
Hamburg, 22609, Germany
Related Publications (2)
Strada L, Schmidt CS, Rosenkranz M, Verthein U, Scherbaum N, Reimer J, Schulte B. Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: A cross-sectional study. Subst Abuse Treat Prev Policy. 2019 Jan 3;14(1):2. doi: 10.1186/s13011-018-0187-9.
PMID: 30606188DERIVEDStrada L, Schulte B, Schmidt CS, Verthein U, Cremer-Schaeffer P, Kruckeberg S, Reimer J. Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol. BMC Infect Dis. 2015 Dec 10;15:563. doi: 10.1186/s12879-015-1307-z.
PMID: 26653754DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jens Reimer, Prof. Dr.
University Medical Center Hamburg-Eppendorf, Centre for Interdisciplinary Addiction Research (CIAR), Hamburg University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Head, Addiction Medicine Unit, University Medical Center Hamburg Eppendorf; Centre for Interdisciplinary Addiction Research (CIAR), Hamburg University
Study Record Dates
First Submitted
March 16, 2015
First Posted
March 23, 2015
Study Start
August 1, 2014
Primary Completion
April 1, 2017
Study Completion
July 1, 2017
Last Updated
May 31, 2017
Record last verified: 2017-05